Company Overview of Tranzyme, Inc.
As of July 15, 2013, Tranzyme, Inc. was acquired by Ocera Therapeutics, Inc., in a reverse merger transaction. Tranzyme, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-based therapeutics primarily in the United States. The company’s pre-clinical product pipeline includes TZP-201, a motilin antagonist, for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, a ghrelin antagonist, for the treatment of metabolic diseases. The company has strategic collaboration with Bristol-Myers Squibb Company to discover, develop, and commercialize additional novel compounds. Tranzyme, Inc. was founded in 1998 and is headquar...
5001 South Miami Boulevard
Durham, NC 27703
Founded in 1998
Key Executives for Tranzyme, Inc.
Tranzyme, Inc. does not have any Key Executives recorded.
Tranzyme, Inc. Key Developments
Tranzyme, Inc. Approves Amendments to the Certificate of Incorporation
Jul 16 13
at the special meeting of its stockholders approved amendments to certificate of incorporation to effect a reverse stock split of Tranzyme's common stock and related matters and approved an amendment to Tranzyme's certificate of incorporation to change the name of Tranzyme to Ocera Therapeutics, Inc.
Tranzyme, Inc.(NasdaqGM:TZYM) dropped from NASDAQ Composite Index
Jul 15 13
Tranzyme, Inc. will be removed from NASDAQ Composite Index.
Tranzyme Receives Non-Compliance Notice From NASDAQ
Jul 3 13
On July 2, 2013, Tranzyme, Inc. received a notice from the Nasdaq Stock Market (NASDAQ) stating that because the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing, as set forth in NASDAQ Listing Rule 5450(a)(1), the Company’s common stock, listed on The NASDAQ Global Market, would be subject to delisting on July 11, 2013 unless the Company requests a hearing before a NASDAQ Hearings Panel (the “Panel”) on or before July 9, 2013. The Company intends to request a hearing before the Panel. The Company believes that such a request will stay any delisting action until after the Company’s expected merger with Ocera Therapeutics, Inc. A special meeting of the Company’s stockholders to approve the Company’s merger with Ocera and other related matters is scheduled for July 15, 2013. The Company expects that NASDAQ’s decision with respect to the listing of the combined company’s common stock on The NASDAQ Global Market will be made around the time of the closing of the Company’s proposed merger with Ocera. The Company has been in active dialogue with NASDAQ regarding the above-described approach to the Notice as well as the initial listing application for the combined company’s shares following the merger with Ocera.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|